We develop label-free optical imaging technologies and quantitative analysis tools to study metabolic heterogeneity in cancer, stem cell function, and immune cell behavior. Optical metabolic imaging (OMI) uses two-photon fluorescence lifetime microscopy of metabolic co-enzymes (NADH and FAD, Fig. 1) to quantify cell redox state and enzyme-binding activity. This approach is advantageous because fluorophores that are already present in the cells can be used to monitor metabolism with single cell resolution. We have developed OMI alongside image analysis tools and population density models to quantify cellular heterogeneity within intact 3D samples. In parallel, we have developed photothermal optical coherence tomography (PT-OCT) to monitor changes in absorber concentrations in the eye and in tumors. Ongoing projects require active collaborations and mentorship of trainees from diverse backgrounds in medicine, engineering, biochemistry, and biology. Please see publications for a comprehensive view of projects and applications of these technologies.
- Optical methods to monitor cell function, metabolism, and cellular diversity
We have developed label-free optical imaging techniques to monitor changes in cellular metabolism with cancer treatment, stem cell differentiation, and immune cell function. Single cell segmentation and population density modeling are used to quantify metabolic diversity within intact samples, and this approach was validated in breast cancer cell lines (Fig. 2A-B). The same approach is under investigation to monitor immune cell function in blood samples (Fig. 2C). Flow cytometry based on NAD(P)H and FAD intensities was optimized for these low-yield autofluorescent molecules, and we successfully performed autofluorescence flow sorting of metabolically distinct breast cancer cell lines. Additional studies characterized NAD(P)H fluorescence lifetimes across a series of metabolic inhibitors to show that NAD(P)H lifetime imaging can distinguish metabolic shunts that do not alter NAD(P)H fluorescence intensities. We have also shown that the fluorescence intensities and lifetimes of NAD(P)H and FAD can discriminate metabolic changes due to distinct phases of the cell cycle on a single cell level, further characterizing these optical signals. Future technology development is focused on label-free quality control techniques for cell manufacturing including CAR T-cell therapies and stem cell therapies.
- Walsh AJ, Mueller KP, Tweed K, Jones I, Walsh CM, Piscopo NJ, Niemi NM, Pagliarini DJ, Saha K, Skala MC. Classification of T-cell activation via autofluorescence lifetime imaging. Nat Biomed Eng. 2021;5(1):77-88. PMCID: PMC7854821.
- Qian T, Heaster TM, Houghtaling AR, Sun K, Samimi K, Skala MC. Label-free imaging for quality control of cardiomyocyte differentiation. Nat Commun. 2021 Jul 28;12(1):4580. PMID: 34321477
- Heaster TM, Humayun M, Yu J, Beebe DJ, Skala MC. Autofluorescence imaging of 3D tumor-macrophage microscale cultures resolves spatial and temporal dynamics of macrophage metabolism. Cancer Res. 2020;80(23):5408-23. PMCID: PMC7718391.
- Sharick JT, Favreau PF, Gillette AA, Sdao SM, Merrins MJ, Skala MC. Protein-bound NAD(P)H Lifetime is Sensitive to Multiple Fates of Glucose Carbon. Sci Rep. 2018;8(1):5456. PMID: 29615678.
- Optical metabolic imaging of organoids for drug development and clinical treatment planning
Optical metabolic imaging is a novel method to monitor cell metabolism within intact organoids so that changes in cell-level metabolic heterogeneity can be monitored over time. Primary tumor organoids are advantageous compared to traditional 2D culture because organoids retain multiple cell types from the original tumor in a 3D environment that maintains the cell-cell communication, genetic expression, and drug response of the original tumor. Primary tumor organoids also provide improved throughput compared to in vivo mouse models. We have shown that optical metabolic imaging accurately predicts drug response in organoids with respect to standard in vivo tumor volume. We further defined metrics of metabolic heterogeneity in tumor organoids that predict drug response across breast, pancreatic, oral, neuroendocrine, and colon cancers (Fig. 3). Current efforts are focused on patient-matched drug screens and developing new drugs that target metabolic heterogeneity in cancer. These methods are also used to monitor, characterize, and provide quality control of organoids derived from stem cells (Fig. 3).
- Datta R, Sivanand S, Lau AN, Florek LV, Barbeau AM, Wyckoff J, Skala MC, Vander Heiden MG. Interactions with stromal cells promote a more oxidized cancer cell redox state in pancreatic tumors. Sci Adv. 2022 Jan 21;8(3):eabg6383. PMID: 35061540.
- Gil DA, Deming D, Skala MC. Patient-derived cancer organoid tracking with wide-field one-photon redox imaging to assess treatment response. J Biomed Opt. 2021 Mar;26(3):036005. PMID: 33754540.
- Sharick JT, Walsh CM, Sprackling CM, Pasch CA, Pham DL, Esbona K, Choudhary A, Garcia-Valera R, Burkard ME, McGregor SM, Matkowskyj KA, Parikh AA, Meszoely IM, Kelley MC, Tsai S, Deming DA, Skala MC. Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment. Front Oncol. 2020;10:553. PMCID: PMC7242740.
- Pasch CA, Favreau PF, Yueh AE, Babiarz CP, Gillette AA, Sharick JT, Karim MR, Nickel KP, DeZeeuw AK, Sprackling CM, Emmerich PB, DeStefanis RA, Pitera RT, Payne SN, Korkos DP, Clipson L, Walsh CM, Miller D, Carchman EH, Burkard ME, Lemmon KK, Matkowskyj KA, Newton MA, Ong IM, Bassetti MF, Kimple RJ, Skala MC, Deming DA. “Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation.” Clin Cancer Res. 2019;25(17):5376-87. PMCID: PMC6726566.
- In vivo optical metabolic imaging of drug response
Mouse models have provided critical in vivo context to validate optical metabolic imaging of cell metabolism. Optical metabolic imaging in vivo provides early (1-3 days post-treatment) measures of drug response compared to standard tumor volume in animal models of cancer. Metabolic diversity within tumors in vivo was defined by a heterogeneity index, derived from similar measures in ecology and information theory. This heterogeneity index also predicts tumor treatment response in vivo early in the course of treatment. Later studies correlated in vivo tumor cell diversity measured with optical metabolic imaging compared to standard immunohistochemical stains. We also experimentally confirmed that metabolic diversity in tumor organoids and matched in vivo tumors is similar under both control and treatment conditions. Later studies defined new statistical frameworks to quantify spatial metabolic diversity in vivo and in organoids. We have now generated mouse models that express fluorescent reporters in macrophages or T cells so that in vivo immune cell metabolism can be monitored in response to cancer immunotherapy. These studies could guide the development of more effective cancer immunotherapies.
- Heaster TM, Heaton AR, Sondel PM, Skala MC. Intravital Metabolic Autofluorescence Imaging Captures Macrophage Heterogeneity Across Normal and Cancerous Tissue. Front Bioeng Biotechnol. 2021 Apr 20;9:644648. PMID: 33959597.
- Sharick JT, Jeffery JJ, Karim MR, Walsh CM, Esbona K, Cook RS, Skala MC. Cellular metabolic heterogeneity in vivo is recapitulated in tumor organoids. Neoplasia. 2019;21(6):615-26. PMCID: PMC6514366.
- Heaster TM, Landman BA, Skala MC. Quantitative spatial analysis of metabolic heterogeneity across in vivo and in vitro tumor models. Front Oncol. 2019;9:1144. PMCID: PMC6839277.
- Walsh AJ, Cook RS, Manning HC, Hicks DJ, Lafontant A, Arteaga CL, Skala MC. Optical metabolic imaging identifies breast cancer glycolytic levels, sub-types, and early treatment response. Cancer Res. 2013;73(20):6164–74. PMCID: PMC3801432.
- Development of photothermal optical coherence tomography (PT-OCT) for molecular imaging
Optical coherence tomography is a powerful 3D imaging tool that is routinely used in clinical ophthalmology. However, it achieves poor molecular specificity. We developed a new technique, photothermal optical coherence tomography (PT-OCT), which enables molecular contrast through microscopic thermoelastic expansions in vivo. Photothermal optical coherence tomography provides molecular contrast in a spatial regime between microscopy (poor penetration depth) and ultrasound (poor resolution). Our work focuses on technology development and in vivo applications in ophthalmology and cancer, using endogenous contrast such as melanin (Fig. 5) and exogenous contrast agents such as indocyanine green.
- Lapierre-Landry M, Huckenpahler AL, Link BA, Collery RF, Carroll J, Skala MC. Imaging Melanin Distribution in the Zebrafish Retina Using Photothermal Optical Coherence Tomography. Transl Vis Sci Technol. 2018;7(5):4. PMCID: PMC6126953.
- Lapierre-Landry M, Connor TB, Carroll J, Tao YK, Skala MC. Photothermal optical coherence tomography of indocyanine green in ex vivo eyes. Opt Lett. 2018;43(11):2470-3. PMID: 29856406.
- Lapierre–Landry M, Gordon AY, Penn JS, Skala MC. In vivo photothermal optical coherence tomography of endogenous and exogenous contrast agents in the eye. Sci Rep. 2017;7(1):9228. PMCID: PMC5569082.
- Tucker-Schwartz JM, Beavers KR, Sit WW, Shah AT, Duvall CL, Skala MC. In vivo imaging of nanoparticle delivery and tumor microvasculature with multimodal optical coherence tomography. Biomed Opt Express. 2014;5(6):1731-43. PMCID: PMC4052907.
- David Beebe, PhD, Pathology & Laboratory Medicine
- Mark Burkard, MD, PhD, Hematology & Oncology
- Paul Campagnola, PhD, Biomedical Engineering
- Christian Capitini, MD, Hematology & Oncology
- Joseph Carroll, PhD, Ophthalmology, Medical College of Wisconsin
- Rebecca Cook, PhD, Cell & Developmental Biology, Vanderbilt University
- Dustin Deming, MD, Hematology & Oncology
- Helen Feltovich, MD, Intermountain Healthcare
- David Gamm, MD, PhD, Ophthalmology & Visual Sciences
- Tim Hall, PhD, Medical Physics
- Laura Knoll, PhD, Medical Microbiology
- Noelle LoConte, MD, Hematology & Oncology
- Kristina Matkowskyj, MD, PhD, Pathology & Laboratory Medicine
- Stephanie McGregor, MD, PhD, Pathology & Laboratory Medicine
- Kris Saha, PhD, Biomedical Engineering
- Paul Sondel, MD, PhD, Hematology & Oncology
- Amy Trentham-Dietz, PhD, Population Health
- Susan Tsai, MD, MHS, Surgical Oncology, Medical College of Wisconsin